Tenax Therapeutics (TENX) Non Operating Investment Income (2014 - 2021)
Tenax Therapeutics (TENX) posted quarterly Non Operating Investment Income of $2.0 for Q4 2021, down 99.79% year-over-year from $973.0 in Q4 2020, and up 100.72% on a QoQ basis from -$276.0 in Q3 2021.
Tenax Therapeutics (TENX) Non Operating Investment Income (2014 - 2021) Analysis & Trends
Tenax Therapeutics has reported Non Operating Investment Income for 8 years, with the latest figure at $2.0 in Q4 2021.
- Non Operating Investment Income for Q4 2021 came in at $2.0, down 99.79% year-over-year; the trailing twelve-month figure through Sep 2022 was $2.0 (down 99.78% YoY), and the FY2021 annual result was -$70.0, down 113.26% from the prior year.
- Non Operating Investment Income advanced to $2.0 in Q4 2021, from -$276.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $10857.0 in Q1 2018 and troughed at -$10556.0 in Q2 2018.
- A 5-year average of -$936.05 and a median of -$202.0 in 2021 frame the typical range for Non Operating Investment Income.
- The widest annual swing landed in 2018, when Non Operating Investment Income soared 265.93%; it then slumped 583.12% in 2020.
- A 5-year view of Non Operating Investment Income shows it stood at $10444.0 in 2017, then tumbled by 200.51% to -$10497.0 in 2018, then jumped by 108.2% to $861.0 in 2019, then gained by 13.01% to $973.0 in 2020, then tumbled by 99.79% to $2.0 in 2021.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were $2.0 in Q4 2021, -$276.0 in Q3 2021, and -$128.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 2.00 |
| Dec 31, 2021 | 2.00 |
| Sep 30, 2021 | -276.00 |
| Sep 30, 2021 | -276.00 |
| Jun 30, 2021 | -128.00 |
| Jun 30, 2021 | -128.00 |
| Mar 31, 2021 | 332.00 |
| Mar 31, 2021 | 332.00 |
| Dec 31, 2020 | 973.00 |
| Dec 31, 2020 | 973.00 |
| Sep 30, 2020 | 1,171.00 |
| Sep 30, 2020 | 1,171.00 |
| Jun 30, 2020 | -3,238.00 |
| Jun 30, 2020 | -3,238.00 |
| Mar 31, 2020 | 1,622.00 |
| Mar 31, 2020 | 1,622.00 |
| Dec 31, 2019 | 861.00 |
| Dec 31, 2019 | 861.00 |
| Sep 30, 2019 | 960.00 |
| Sep 30, 2019 | 960.00 |